Table 2.
Deaths and vascular occlusive events by treatment allocation
|
CRASH-2 trial |
WOMAN trial |
Total |
||||
|---|---|---|---|---|---|---|
| Tranexamic acid (n=10 060) | Placebo (n=10 067) | Tranexamic acid (n=10 034) | Placebo (n=9977) | Tranexamic acid (n=20 094) | Placebo (n=20 044) | |
| Any cause of death | 1463 (14·5%) | 1613 (16·0%) | 227 (2·3%) | 255 (2·6%) | 1690 (8·4%) | 1868 (9·3%) |
| Death due to bleeding | 489 (4·9%) | 574 (5·7%) | 155 (1·5%) | 190 (1·9%) | 644 (3·2%) | 764 (3·8%) |
| Non-bleeding death | 974 (9·7%) | 1039 (10·3%) | 72 (0·7%) | 65 (0·7%) | 1046 (5·2%) | 1104 (5·5%) |
| Vascular occlusive events | 168 (1·7%) | 201 (2·0%) | 31 (0·3%) | 34 (0·3%) | 199 (1·0%) | 235 (1·2%) |
| Vascular death | 33 (0·3%) | 48 (0·5%) | 10 (0·1%) | 11 (0·1%) | 43 (0·2%) | 59 (0·3%) |
| Myocardial infarction* | 35 (0·4%) | 55 (0·5%) | 2 (0·0%) | 3 (0·0%) | 37 (0·2%) | 58 (0·3%) |
| Stroke* | 57 (0·6%) | 66 (0·7%) | 8 (0·1%) | 6 (0·1%) | 65 (0·3%) | 72 (0·4%) |
| Pulmonary embolism* | 72 (0·7%) | 71 (0·7%) | 17 (0·2%) | 20 (0·2%) | 89 (0·4%) | 91 (0·5%) |
| Deep vein thrombosis* | 40 (0·4%) | 41 (0·4%) | 3 (0·0%) | 7 (0·1%) | 43 (0·2%) | 48 (0·2%) |
*
Includes both fatal and non-fatal events.